Contributors: National Institutes of Health Bethesda, MD, USA (NIH); Bill & Melinda Gates Medical Research Institute Cambridge; PATH Seattle; Antigen Discovery Inc Irvine, CA, USA (ADI); University of Bergen (UiB); Haukeland University Hospital; Organisation Mondiale de la Santé / World Health Organization Office Genève, Suisse (OMS / WHO); Université libre de Bruxelles (ULB); Latham BioPharm Group Elkridge, MD, USA; Jenner Institute Oxford; University of Oxford; New York State Department of Health Albany; United States Pharmacopeial Convention (USP); Kenya Medical Research Institute (KEMRI); University of Maryland Baltimore; University of Washington Seattle; Institut Pasteur Paris (IP); Naval Medical Research Center Silver Spring, USA (NMRC); Emory University Atlanta, GA; This work was supported by the Bill & Melinda Gates Foundation INV-000875 . Under the grant conditions of the Foundation, a CreativeCommons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.
Abstract: International audience ; The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This international gathering focused on cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. In addition to the conference’s plenary content, the agenda featured ten breakout workshops on topics of importance to the enteric vaccine field. This unique aspect of VASE Conferences allows focused groups of attendees to engage in in-depth discussions on subjects of interest to the enteric vaccine development community. In 2022, the workshops covered a range of topics. Two focused on the public health value of enteric vaccines, with one examining how to translate evidence into policy and the other on the value proposition of potential combination vaccines against bacterial enteric pathogens. Two more workshops explored new tools for the development and evaluation of vaccines, with the first on integrating antigen/antibody technologies for mucosal vaccine and immunoprophylactic development, and the second on adjuvants specifically for Shigella vaccines for children in low- and middle-income countries. Another pair of workshops covered the status of vaccines against two emerging enteric pathogens, Campylobacter and invasive non-typhoidal Salmonella. The remaining four workshops examined the assessment of vaccine impact on acute and long-term morbidity. These included discussions on the nature and severity of intestinal inflammation; cellular immunity and immunological memory in ETEC and Shigella infections; clinical and microbiologic endpoints for Shigella vaccine efficacy studies in children; and intricacies of protective immunity to enteric pathogens. This article provides a brief summary of the presentations and discussions at each workshop ...
Processing Request
No Comments.